Among the 718 breast cancer patients with tumor tissue included in the TMA, CAP1 expression was assessable in 669 tumors (Fig. 1), of which 106 tumors (15.8%) displayed a low, 273 (40.8%) moderate, and 290 (43.3%) high CAP1 expression. This evidence concerns the gene CAP1 and breast carcinoma.